NTRK1 and cancer: Larotrectinib is a selective inhibitor of the Trk proteins (including TrkA, TrkB, and TrkC) approved by the American Food and Drug Administration (FDA) in 2018 for the treatment of adult and paediatric patients with any advanced cancer with a Trk fusion protein after progression following standard treatment or who lack a satisfactory alternative treatment [35].